Business
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time. Attendance for the event requires registration.
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio Ltd.","displaySize":"","headline":null,"caption":"Entera Bio Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/f99611d3ae782150e893e9b0080a2af6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xxwg6MzoLJolPtGE.3oX7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/f99611d3ae782150e893e9b0080a2af6","width":150,"height":87}},"lazy":false},{"type":"text","content":"TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time.","length":451,"tagName":"p"},{"type":"text","content":"Attendance for the event requires registration. Participants may register at the following link: https://events.zoom.us/ev/AjJwNRe2lJ20ip76GJ4k0Ee_SLHBTKEcb9Iabu7PDwVyGRBCzqr_~AqIJON0d6_lhurfYvEmThe3o4X3G0iFAy9zFmuBnQMCqifflBtC23k66Fg","length":234,"tagName":"p"},{"type":"text","content":"The roundtable discussion with Entera’s Chief Executive Officer Miranda Toledano and key opinion leaders in osteoporosis treatment, clinical research and women’s health will focus on women’s bone health during and after menopause, the current treatment paradigm in osteoporosis management, anabolic therapies in clinical practice, and how EB613 may potentially fit within the future treatment landscape as the first oral anabolic candidate.","length":440,"tagName":"p"},{"type":"text","content":"The event will feature a discussion with the following experts:","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Felicia Cosman, Professor of Medicine at Columbia University and a globally recognized authority in osteoporosis and anabolic therapies","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Steven Goldstein, Professor of Obstetrics and Gynecology at New York University Grossman School of Medicine and former President of both the International Menopause Society and the North American Menopause ...